Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

IVVD - Invivyd, Inc. So'nggi Yangiliklar | Finranks

Home

IVVD

I

Invivyd, Inc. (IVVD)

NGM – Real vaqt narxi. Valyuta: USD

1.37

-0.14 (-9.27%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.45

+0.08 (5.84%)

Bozordan keyin: Mar 27, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Invivyd, Inc. is advancing VYD2311, a next-gen monoclonal antibody for COVID-19 prevention, with pivotal Phase 3 DECLARATION data expected mid-2026. IVVD's Pemgarda generated $53.4M in 2025 revenue, but fell short of management expectations; net loss narrowed to $(52.5M) from $(170M) prior year. IVVD secured FDA Fast Track for VYD2311 and raised ~$200M in 2H 2025, providing at least two years of funding at current burn rates.

Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript

Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript

Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Michael Mina, M.D., Ph.D., as Chief Medical Officer.

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m.

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

NEW HAVEN, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY pivotal clinical trial of Invivyd's monoclonal antibody pemivibart to predict clinical protection levels from COVID purely from laboratory-determined serum monoclonal antibody activity levels, irrespective of virus variation. This newly published analysis builds on similar, earlier peer-reviewed analyses1 demonstrating similar findings from pre-Omicron virus variants with a prior Invivyd antibody. Together these findings support a correlate of protection for Invivyd's COVID-directed monoclonal antibodies, a critical relationship for understanding antibody-mediated protection from COVID, and a potentially useful tool to support clinical decision making, COVID antibody regulation, and overall stewardship of public health.

Videolar

No Data

There is no data to display

Press-relizlar

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Michael Mina, M.D., Ph.D., as Chief Medical Officer.

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

NEW HAVEN, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY pivotal clinical trial of Invivyd's monoclonal antibody pemivibart to predict clinical protection levels from COVID purely from laboratory-determined serum monoclonal antibody activity levels, irrespective of virus variation. This newly published analysis builds on similar, earlier peer-reviewed analyses1 demonstrating similar findings from pre-Omicron virus variants with a prior Invivyd antibody. Together these findings support a correlate of protection for Invivyd's COVID-directed monoclonal antibodies, a critical relationship for understanding antibody-mediated protection from COVID, and a potentially useful tool to support clinical decision making, COVID antibody regulation, and overall stewardship of public health.